Early Trial Shows Up to 92% Response Rate for Novel Lung Cancer Combination
In a preliminary trial, a PD-L1/VEGF bispecific antibody combined with an antibody-drug conjugate produced response rates ranging from 52.4% in third-line therapy to 92.3% in first-line treatment of advanced small cell lung cancer. The safety profile was favorable, with mostly low-grade adverse events and a low rate of interstitial lung disease. The results were presented at the World Conference on Lung Cancer and support further clinical development of the combination.
The BNT324-01 trial enrolled patients regardless of PD-L1 expression across centers in North America, Europe, Asia, and Australia. Beyond tumor shrinkage, circulating tumor DNA declined substantially in 96% of evaluable patients, providing molecular corroboration of clinical activity. The regimen's side-effect profile reflected the known toxicities of each agent individually, with most events mild and interstitial lung disease occurring infrequently.
The two drugs attack cancer through complementary routes—pumitamig blocks immune evasion and angiogenesis pathways while elfe-D delivers a cytotoxic payload directly to tumor cells. Preclinical xenograft studies demonstrated durable tumor regression with the combination compared with either agent alone. The regimen is also being evaluated in non-small cell lung cancer, with additional tumor-type data expected at the European Society for Medical Oncology meeting later this year.
If confirmed in larger randomized trials, this combination could meaningfully expand treatment options for small cell lung cancer, a disease with historically poor survival. The high response rates across multiple lines of therapy—including patients who progressed on existing immunotherapies—may offer new hope for a population with few alternatives. However, the discussant's caution about whether the bispecific adds genuine benefit over the ADC alone underscores the need for rigorous comparative studies before this approach could alter standard practice.